Multiple Endocrine Neoplasia Type 1 Regulates TGFβ-Mediated Suppression of Tumor Formation and Metastasis in Melanoma
Cells · 2024
DOI: 10.3390/cells13110973 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, 2024. Verfasst von Julien Boudreault und 9 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Research Program, Department of Medicine, Research Institute of McGill University Health Center, Montreal, QC H4A 3J1, Canada. Hauptthemen laut MEDLINE: Melanoma, Transforming Growth Factor beta, Signal Transduction. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: CIHR, Canadian Institutes for Health Research.
Abstract (Originalsprache)
Over the past few decades, the worldwide incidence of cutaneous melanoma, a malignant neoplasm arising from melanocytes, has been increasing markedly, leading to the highest rate of skin cancer-related deaths. While localized tumors are easily removed by excision surgery, late-stage metastatic melanomas are refractory to treatment and exhibit a poor prognosis. Consequently, unraveling the molecular mechanisms underlying melanoma tumorigenesis and metastasis is crucial for developing novel targeted therapies. We found that the multiple endocrine neoplasia type 1 (MEN1) gene product Menin is required for the transforming growth factor beta (TGFβ) signaling pathway to induce cell growth arrest and apoptosis in vitro and prevent tumorigenesis in vivo in preclinical xenograft models of melanoma. We further identified point mutations in two MEN1 family members affected by melanoma that led to proteasomal degradation of the MEN1 gene product and to a loss of TGFβ signaling. Interestingly, blocking the proteasome degradation pathway using an FDA-approved drug and RNAi targeting could efficiently restore MEN1 expression and TGFβ transcriptional responses. Together, these results provide new potential therapeutic strategies and patient stratification for the treatment of cutaneous melanoma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cancer Research Program, Department of Medicine, Research Institute of McGill University Health Center, Montreal, QC H4A 3J1, Canada.
- Division of Medical Genetics, Fondazione IRCCS Casa Sollievo della Sofferenza, 71013 San Giovanni Rotondo, Italy.
- Endocrinology and Metabolism Unit, University-Hospital S. Maria della Misericordia, 33100 Udine, Italy.
- Endocrinology Unit, Fondazione IRCCS Casa Sollievo della Sofferenza, 71013 San Giovanni Rotondo, Italy.
ORCID-Profile: Lucie Canaff, David Goltzman
Förderung
- CIHR
- Canadian Institutes for Health Research
Zitieren
APA
Boudreault, J., Canaff, L., Ghozlan, M., Wang, N., Guarnieri, V., Salcuni, A. S., Scillitani, A., Goltzman, D., Ali, S., & Lebrun, J. J. (2024). Multiple Endocrine Neoplasia Type 1 Regulates TGFβ-Mediated Suppression of Tumor Formation and Metastasis in Melanoma. Cells. https://doi.org/10.3390/cells13110973
Vancouver
Boudreault J, Canaff L, Ghozlan M, Wang N, Guarnieri V, Salcuni AS, et al. Multiple Endocrine Neoplasia Type 1 Regulates TGFβ-Mediated Suppression of Tumor Formation and Metastasis in Melanoma. Cells. 2024. doi:10.3390/cells13110973
BibTeX
@article{Boudreault2024,
author = {Boudreault, Julien and Canaff, Lucie and Ghozlan, Mostafa and Wang, Ni and Guarnieri, Vito and Salcuni, Antonio Stefano and Scillitani, Alfredo and Goltzman, David and Ali, Suhad and Lebrun, Jean-Jacques},
title = {Multiple Endocrine Neoplasia Type 1 Regulates TGFβ-Mediated Suppression of Tumor Formation and Metastasis in Melanoma},
journal = {Cells},
year = {2024},
doi = {10.3390/cells13110973}
}
EUVIMED